Bank of America’s Vanda Pharmaceuticals VNDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.33M Buy
191,927
+110,513
+136% +$852K ﹤0.01% 4356
2025
Q4
$718K Sell
81,414
-25,022
-24% -$138K ﹤0.01% 4704
2025
Q3
$531K Sell
106,436
-43,035
-29% -$199K ﹤0.01% 5750
2025
Q2
$706K Buy
149,471
+27,909
+23% +$122K ﹤0.01% 5510
2025
Q1
$558K Sell
121,562
-6,774
-5% -$31.6K ﹤0.01% 5592
2024
Q4
$615K Buy
128,336
+28,659
+29% +$138K ﹤0.01% 5388
2024
Q3
$467K Buy
99,677
+22,259
+29% +$119K ﹤0.01% 5525
2024
Q2
$437K Sell
77,418
-1,130,843
-94% -$5.84M ﹤0.01% 5427
2024
Q1
$4.97M Buy
1,208,261
+1,181,116
+4,351% +$4.73M ﹤0.01% 3617
2023
Q4
$115K Sell
27,145
-15,334
-36% -$61.9K ﹤0.01% 6326
2023
Q3
$184K Sell
42,479
-296,446
-87% -$1.65M ﹤0.01% 5945
2023
Q2
$2.23M Sell
338,925
-1,292,215
-79% -$8.28M ﹤0.01% 4124
2023
Q1
$11.1M Buy
1,631,140
+1,345,529
+471% +$9.46M ﹤0.01% 2723
2022
Q4
$2.11M Sell
285,611
-62,314
-18% -$607K ﹤0.01% 4209
2022
Q3
$3.44M Sell
347,925
-130,784
-27% -$1.38M ﹤0.01% 3746
2022
Q2
$5.22M Buy
478,709
+167,879
+54% +$1.74M ﹤0.01% 3342
2022
Q1
$3.52M Sell
310,830
-77,220
-20% -$1.02M ﹤0.01% 3998
2021
Q4
$6.09M Buy
388,050
+80,274
+26% +$1.4M ﹤0.01% 3450
2021
Q3
$5.28M Buy
307,776
+29,713
+11% +$520K ﹤0.01% 3510
2021
Q2
$5.98M Buy
278,063
+25,551
+10% +$457K ﹤0.01% 3356
2021
Q1
$3.79M Buy
252,512
+33,549
+15% +$543K ﹤0.01% 3679
2020
Q4
$2.88M Sell
218,963
-71,805
-25% -$864K ﹤0.01% 3627
2020
Q3
$2.81M Buy
290,768
+47,367
+19% +$506K ﹤0.01% 3412
2020
Q2
$2.79M Buy
243,401
+8,442
+4% +$95.6K ﹤0.01% 3353
2020
Q1
$2.44M Buy
234,959
+42,779
+22% +$530K ﹤0.01% 3332
2019
Q4
$3.15M Sell
192,180
-33,829
-15% -$511K ﹤0.01% 3646
2019
Q3
$3M Sell
226,009
-243,589
-52% -$3.39M ﹤0.01% 3682
2019
Q2
$6.62M Sell
469,598
-151,052
-24% -$2.4M ﹤0.01% 2960
2019
Q1
$11.4M Buy
620,650
+314,638
+103% +$7.17M ﹤0.01% 2353
2018
Q4
$8M Sell
306,012
-21,618
-7% -$508K ﹤0.01% 2518
2018
Q3
$7.52M Buy
327,630
+137,694
+72% +$2.81M ﹤0.01% 2785
2018
Q2
$3.62M Buy
189,936
+6,040
+3% +$101K ﹤0.01% 3460
2018
Q1
$3.1M Buy
183,896
+14,741
+9% +$247K ﹤0.01% 3511
2017
Q4
$2.57M Sell
169,155
-22,129
-12% -$328K ﹤0.01% 3736
2017
Q3
$3.42M Buy
191,284
+73,034
+62% +$1.22M ﹤0.01% 3526
2017
Q2
$1.93M Buy
118,250
+48,435
+69% +$698K ﹤0.01% 3919
2017
Q1
$977K Buy
69,815
+9,439
+16% +$135K ﹤0.01% 4446
2016
Q4
$963K Buy
60,376
+23,071
+62% +$371K ﹤0.01% 4373
2016
Q3
$621K Buy
37,305
+899
+2% +$12.1K ﹤0.01% 4481
2016
Q2
$407K Buy
36,406
+17,514
+93% +$170K ﹤0.01% 4784
2016
Q1
$158K Sell
18,892
-12,568
-40% -$103K ﹤0.01% 5265
2015
Q4
$293K Buy
31,460
+44
+0.1% +$439 ﹤0.01% 5129
2015
Q3
$354K Sell
31,416
-27,852
-47% -$341K ﹤0.01% 5026
2015
Q2
$752K Buy
59,268
+2,761
+5% +$29.8K ﹤0.01% 4355
2015
Q1
$526K Buy
56,507
+47,864
+554% +$541K ﹤0.01% 4280
2014
Q4
$124K Sell
8,643
-5,778
-40% -$68.4K ﹤0.01% 5735
2014
Q3
$149K Buy
14,421
+281
+2% +$3.68K ﹤0.01% 5678
2014
Q2
$229K Buy
14,140
+6,194
+78% +$82.5K ﹤0.01% 5429
2014
Q1
$129K Sell
7,946
-111,302
-93% -$1.58M ﹤0.01% 5771
2013
Q4
$1.48M Sell
119,248
-122,674
-51% -$1.23M ﹤0.01% 3638
2013
Q3
$2.65M Buy
241,922
+1,731
+0.7% +$18.5K ﹤0.01% 2973
2013
Q2
$1.94M Buy
+240,191
New +$1.62M ﹤0.01% 3245

Other funds holding VNDA

Bank of America's VNDA Position: Q1 2026 in Review

Bank of America increased its Vanda Pharmaceuticals (VNDA) stake by 136% in Q1 2026, buying an estimated $852K and bringing the position to 191,927 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #4356.

Bank of America first reported a position in VNDA in Q2 2013 and has held it in 52 quarters since. The position peaked at $11.4M in Q1 2019. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Bank of America held 191,927 shares of Vanda Pharmaceuticals worth $1.33M as of Q1 2026.
  • Bank of America bought 110,513 Vanda Pharmaceuticals shares in Q1 2026, an estimated $852K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #4356 holding.
  • Bank of America first reported a position in Vanda Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Bank of America's Vanda Pharmaceuticals position peaked at $11.4M in Q1 2019.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.